je.st
news
Tag: biosimilar
Amgen: Its biosimilar version of Humira about as effective
2015-02-04 00:09:02| Biotech - Topix.net
Biologic drugmaker Amgen says its biosimilar version of rheumatoid arthritis drug Humira worked similarly in a key head-to-head test. Amgen Inc. says its ABP 501 produced similar results in the percentage of patients in the 26-week, late-stage study who saw improvements in pain, ability to function and number of swollen and tender joints.
Tags: version
effective
amgen
humira
Biosimilar drug developer Coherus jumps into IPO pool
2014-09-26 22:52:09| Biotech - Topix.net
The Redwood City company, which raised $55 million in May , is the latest Bay Area life sciences company in an increasingly deep and rich list of potential IPOs. Last week, for example, dermatology drug developer Dermira Inc. of Redwood City and Calithera Biosciences Inc. of South San Francisco boosted their IPO targets.
FDA reviewing what could be first biosimilar drug
2014-07-25 01:43:50| Biotech - Topix.net
Nearly five years after Congress passed a law enabling future approval of biosimilars, for the first time the FDA has accepted an application to sell a similar, but not identical, version of a biologic drug.
Tags: drug
reviewing
fda
biosimilar
Indiana Senate Passes Legislation to Ensure Safe Access to Biosimilar Therapies
2014-01-30 06:00:00| Industrial Newsroom - All News for Today
BIO and Indiana Health Industry Forum commend Indiana State Senate for passing legislation designed to create pathway for the substitution of interchangeable biologic medicines. Legislation ensures transparency and communication between patients and their treatment teams. Policies outlined in the identical SB 262 align with BIO’s principles on biologic substitution, therefore BIO and IHIF support passage of this bill as it moves along for consideration by the Indiana House of ...This story is related to the following:Trade Associations
Tags: access
safe
ensure
indiana
Biogen Idec, Samsun BIoepis in Biosimilar Deal
2013-12-18 06:36:36| Biotech - Topix.net
CAMBRIDGE, Mass. & SEOUL, Korea, Dec. 17, 2013--Biogen Idec and Samsung Bioepis today announced that through their joint venture, Biogen Idec has exercised its right to enter into an agreement to commercialize anti-TNF biosimilar product candidates in Europe, including biosimilars for widely used therapies to treat conditions such as rheumatoid ... (more)